Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Title Page
Serum nardilysin, a surrogate marker for epithelial-mesenchymal transition,
predicts prognosis of intrahepatic cholangiocarcinoma after surgical resection
5
Authors
Tomoaki Yoh1), Etsuro Hatano2), Yosuke Kasai1), Hiroaki Fuji1), Kiyoto Nishi3), Kan Toriguchi2),
Hideaki Sueoka2), Mikiko Ohno4), Satoru Seo1), Keiko Iwaisako5), Kojiro Taura1), Rina
Yamaguchi6), Masato Kurokawa6), Jiro Fujimoto2), Takeshi Kimura3), Shinji Uemoto1), Eiichiro
10 Nishi4)
Affiliations
1) Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2) Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
15 3) Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University,
Kyoto, Japan
4) Department of Pharmacology, Shiga University of Medical Science, Otsu, Japan
5) Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University,
Kyotanabe, Japan
20 6) Sanyo Chemical Industries Ltd., Kyoto, Japan
Corresponding author:
Eiichiro Nishi, MD, PhD
Department of Pharmacology, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu,
25 520-2192, Japan
Tel.: +81-77-548-2181, Fax: +81-77-548-2183, E-mail: [email protected]
1
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Etsuro Hatano, MD, PhD
Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo,
663-8501, Japan
Tel.: +81-798-45-6582, Fax: +81-798-45-6581, E-mail: [email protected]
5
Running title:
Nardilysin is a novel prognostic biomarker for ICC
Key words:
10 Intrahepatic cholangiocarcinoma, nardilysin, epithelial-mesenchymal transition, biomarker, surgery
Conflicts of Interest:
The authors declare no conflict of interest.
15 Abbreviations
ICC: intrahepatic cholangiocarcinoma
HCC: hepatocellular carcinoma
OS: overall survival
NRDC: nardilysin (N-arginine dibasic convertase)
20 HB-EGF: heparin-binding epidermal growth factor
TNF-α: tumor necrosis factor-α
ADAM: a disintegrin and metalloproteinase
HDAC3: Histone deacetylase 3
PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha
25 IHC: immunohistochemistry
AJCC: American Joint Committee on Cancer
2
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
ELISA: enzyme-linked immunosorbent assay
CM: condition medium
FBS: fetal bovine serum
5 KD: knockdown
NC: negative control
qRT-PCR: quantitative real-time polymerase chain reaction
WST-8: tetrazolium salt-based proliferation assay
CCK8: Cell Counting Kit-8
10 PBS: Phosphate-buffered saline
GAPDH: glyceraldehyde-3-phosphate dehydrogenase
DFS: disease-free survival
ROC: receiver operating characteristic
AUC: area under the curve
15 SD: standard deviation
HC: healthy controls
LN: lymph node
CEA: Carcinoembryonic antigen
CA19-9: carbohydrate antigen 19-9
20 EMT: epithelial-mesenchymal transition
ZEB1: zinc finger E-box binding homeobox 1
EMT-TFs: EMT-inducing transcription factors
SOX2: sex-determining region Y-box 2
CSC: cancer stem cell
25 HIF-1α: hypoxia-inducible factor-1α
IGF-1: insulin-like growth factors-1
3
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
TGF-β: transforming growth factor-β
EGF: epidermal growth factor
4
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Abstract
Purpose:
Few studies have investigated prognostic biomarkers in patients with intrahepatic
5 cholangiocarcinoma (ICC). Nardilysin (NRDC), a metalloendopeptidase of the M16 family, has
been suggested to play important roles in inflammation and several cancer types. We herein
examined the clinical significance and biological function of NRDC in ICC.
Experimental Design:
We measured serum NRDC levels in 98 ICC patients who underwent surgical resection in two
10 independent cohorts to assess its prognostic impact. We also analyzed NRDC mRNA levels in
cancerous tissue specimens from 43 ICC patients. We investigated the roles of NRDC in cell
proliferation, migration, gemcitabine sensitivity, and gene expression in ICC cell lines using gene
silencing.
Results:
15 High serum NRDC levels were associated with shorter overall survival and disease-free survival in
the primary (n=79) and validation (n=19) cohorts. A correlation was observed between serum
protein levels and cancerous tissue mRNA levels of NRDC (Spearman’s ρ=0.413, p=0.006). The
gene knockdown of NRDC in ICC cell lines attenuated cell proliferation, migration, and tumor
growth in xenografts, and increased sensitivity to gemcitabine. The gene knockdown of NRDC was
20 also accompanied by significant changes in the expression of several epithelial-mesenchymal
transition (EMT)-related genes. Strong correlations were observed between the mRNA levels of
NRDC and EMT-inducing transcription factors, ZEB1 and SNAI1, in surgical specimens from ICC
patients.
Conclusions:
25 Serum NRDC, a possible surrogate marker reflecting the EMT state in primary tumors, predicts the
outcome of ICC after surgical resection.
5
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Translational Relevance Few studies have investigated prognostic biomarkers in intrahepatic cholangiocarcinoma (ICC) that
5 may contribute to establishing adjuvant strategies. Nardilysin (NRDC), a metalloendopeptidase of
the M16 family, has been suggested to play important roles in inflammation and several cancer
types. The present results revealed 1) a correlation between serum NRDC levels and cancerous
tissue mRNA levels of NRDC, 2) that preoperative serum NRDC levels were associated with
survival and recurrence, and 3) strong correlations between the mRNA levels of NRDC and EMT-
10 inducing transcription factors, ZEB1 and SNAI1, in ICC cell lines and cancerous tissue. Based on
the potential relationship between NRDC and EMT, the preoperative evaluation of serum NRDC
has potential as a clinical tool for predicting the postoperative outcomes of ICC patients undergoing
surgical resection.
6
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer following
hepatocellular carcinoma (HCC), accounting for 5-15% of all primary liver cancers [1-3]. There are
marked geographic variations in the incidence of ICC, with a higher incidence in East Asia, while
5 the number of ICC patients has been reported to be increasing worldwide [3, 4]. The survival rate of
ICC patients is poor because of the late presentation of the disease and limited therapies. Although
surgical resection is the only curative treatment, 30-40% of ICC patients have surgical indications
[3]. Moreover, the recurrence rate after surgical resection is 50–60% and the 5-year overall survival
(OS) rate after surgical resection is only 25–31% [3, 5, 6], highlighting the need to optimize
10 adjuvant strategies. Recent evidence has suggested that adjuvant chemotherapy is associated with
prolonged survival, particularly in some advanced cases [7, 8]. However, there are no established
methods to define patient subgroups that need adjuvant strategies. The preoperative measurement of
serum tumor markers may identify high-risk patients; however, few studies have investigated
biomarkers in ICC patients possibly due to the difficulties associated with collecting large numbers
15 of serum samples from ICC patients [9-11].
Nardilysin (N-arginine dibasic convertase, NRDC) is a zinc peptidase of the M16 family
that selectively cleaves dibasic sites [12, 13]. NRDC exhibits widespread expression throughout the
body, and regulates multiple biological processes, such as myelination [14], body temperature
homeostasis [15], and insulin secretion [16]. Although NRDC is a soluble cytosolic protein without
20 an obvious signal peptide or nuclear localization signal, it shuttles between the cytoplasm and
nucleus and is secreted via an as yet unknown mechanism [17]. We identified NRDC as a specific
binding partner of heparin-binding epidermal growth factor-like growth factor (HB-EGF). Our
subsequent studies demonstrated that NRDC enhanced the ectodomain shedding of HB-EGF and
other membrane proteins, such as tumor necrosis factor-alpha (TNF-α), through the activation of
25 disintegrin and metalloproteinase (ADAM) proteases [18,19]. In addition to its extracellular
functions, we recently clarified the nuclear functions of NRDC as a transcriptional co-regulator,
7
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
which modulates the transcriptional activity of Histone deacetylase 3 (HDAC3) [20], peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) [15], and islet-1 [16].
Furthermore, NRDC is strongly expressed in several cancer types, promotes tumor growth [19, 21-
23], and is associated with a poor prognosis [19, 22, 23], suggesting important roles for NRDC in
5 tumor biology. Our recent findings also indicated the clinical usefulness of serum NRDC in specific
clinical settings. For example, serum NRDC levels were associated with the survival outcomes of
postoperative HCC patients with hepatitis C [23].
In the present study, we retrospectively investigated serum expression levels of NRDC in
ICC patients who underwent surgical resection to clarify whether serum NRDC has potential as a
10 postoperative prognostic indicator. We also examined NRDC mRNA expression in surgical
specimens resected from patients as well as the pathophysiological role of NRDC in ICC using an
RNA interference method in ICC cell lines.
8
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Materials and Methods
Study design and population
5 This study was designed to investigate whether serum NRDC has the ability to predict the outcomes
of ICC patients after surgical resection. We analyzed serum NRDC levels in two independent
cohorts: a primary cohort at Kyoto University and an external validation cohort at Hyogo College of
Medicine. In the primary cohort, we analyzed 79 consecutive patients with ICC who underwent
surgical resection at Kyoto University Hospital (Kyoto, Japan) between January 2006 and July
10 2013. In the validation cohort, we analyzed 19 consecutive patients with ICC who underwent
surgical resection at Hyogo College of Medicine (Nishinomiya, Japan) between January 2009 and
January 2015. The final diagnosis of ICC was histologically confirmed. The follow-up data of the
primary and validation cohorts were updated in April 2017 and February 2018, respectively. The
surgical procedure in the primary cohort was reported previously [6, 7, 9]. Serum samples from ICC
15 patients (n=98) were obtained preoperatively at the time of admission. Fresh frozen cancer tissues
were obtained from 43 out of 79 ICC patients in the primary cohort, from which mRNA was
isolated. Surgical specimens from 20 out of the 43 ICC patients were also assessed by
immunohistochemistry (IHC).
Clinicopathological and survival data were extracted from a prospectively maintained
20 institutional database. Clinicopathological data, including gender, age, hepatitis virus markers, the
Child-Pugh classification, primary tumor characteristics, and treatment-related variables, were
collected. Tumor characteristics and resection margins were ascertained based on a final
pathological assessment. The tumor stage was assessed by the 7th edition of the American Joint
Committee on Cancer (AJCC) classification [24]. Post-surgical adjuvant chemotherapy was
25 administered using gemcitabine (from 2006) and/or tegafur-gimeracil-oteracil potassium (S-1; from
9
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
2007) for tumors classified as stage II–IV according to the AJCC classification (from 2006).
Recurrence was diagnosed based on imaging studies and tumor markers.
Written informed consent for the use of serum and resected tissue samples was obtained
from all patients in accordance with the Declaration of Helsinki, and this study was approved by the
5 institutional review committee of the Graduate School of Medicine, Kyoto University (approval
code: R803-1) and Hyogo College of Medicine (approval code: 201807-010).
Measurement of serum NRDC levels
10 Serum was isolated from whole blood and stored at -80C until analyzed. To quantify serum NRDC
levels, an enzyme-linked immunosorbent assay (ELISA) was performed according to a previously
described method [25]. Briefly, to establish a sandwich ELISA system, all combinations of the 7
monoclonal antibodies for NRDC were tested, and the optimum combination of clone #231 for
coating and #304 for detection was selected. An automated analyzer for the chemiluminescent
15 enzyme immunoassay, SphereLight 180 (Olympus, Tokyo, Japan), was utilized to measure serum
NRDC levels according to the manufacturer’s protocol.
Cell culture and preparation of condition medium (CM)
20 The human ICC cell lines HuCCT-1 and HuH28 were provided by the Japanese Collection of
Research Bioresources Cell Bank (Osaka, Japan) and SSP-25 by the RIKEN Bioresource Center
(Tsukuba, Japan). ICC cells were grown in RPMI 1640 media supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin and streptomycin. The human colorectal cancer cell line HCT116
was provided by the American Type Culture Collection (Rockville, TX, USA) and 293 T cells by
25 the RIKEN Bioresource Center (Tsukuba, Japan). These cells were growth in DMEM medium
supplemented with 10% FBS and antibiotics. Cells were cultured at 37C under 5% CO2 and 95%
10
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
relative humidity. These cells were incubated in serum-free medium for 24 h before the initiation of
experiments. To prepare CM, confluent monolayers of ICC cells were incubated in RPMI 1640
medium supplemented with 0.1% bovine serum albumin for 48 h. Cultured media were collected
and centrifuged at 3,000 rpm at 4°C for 10 min, and the supernatant was harvested.
5
Gene knockdown of NRDC
The gene knockdown (KD) of NRDC in ICC cells was performed by the transfection of lentiviral
vectors expressing miRNA as previously reported [19, 23]. The sequences targeting the NRDC gene
10 were as follows: NRDC-KD1: 5’-CTGATGCAAACAGAAAGGAAA-3’; NRDC-KD2: 5’-
GAGAAATGGTTTGGAACTCAA-3’. We used a control vector that contains a non-targeting
sequence for any vertebrate gene as a negative control (NC). The efficiency of the gene KD of
NRDC was evaluated by Western blotting and quantitative real-time polymerase chain reaction
(qRT- PCR) analyses.
15
Cell proliferation assay
Cell proliferation was examined by a tetrazolium salt-based proliferation assay (WST-8 assay)
using Cell Counting Kit-8 (CCK8, Dojindo Laboratories, Tokyo, Japan). Briefly, 96-well plates
20 were seeded with cells at a density of 5000-10000 cells per well (HuCCT-1: 1.0 × 104 cells, SSP-
25: 5 x 103cell per well) and cultured for 72 h. Ten microliters of CCK8 solution was added to each
well and incubated at 37°C for 2 h. The cell viability ratio was defined as the ratio of absorbance at
450 nm of KD and NC cells. All assays were performed in quadruplicate and repeated at least three
times.
25
Migration assay
11
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
The migration of ICC cells was examined using a wound healing assay and chemotaxis assay as
previously reported [26]. In the wound healing assay, confluent ICC cells in 24-well plates were
wounded using a sterile 200-μl pipette tip. Cells were then grown for an additional 12 and 24 h with
5 serum-free media. Wound closure was observed with an inverted microscope (Keyence, Osaka,
Japan) at 40×magnification. The cell migration distance was measured using ImageJ software
(National Institute of Health) and compared with baseline measurements. All assays were repeated
at least three times.
A chemotaxis assay was performed in 8-μm pore Transwell® chambers (Corning Costar,
10 Cambridge, MA, USA). Briefly, ICC cells (HuCCT-1: 5.0 ×104 cells, SSP-25: 2.0×104 cells) in
serum-free media were placed in the upper chamber. The lower chamber was filled with 750 ml of
RPMI 1640 supplemented with 10% FBS as a chemoattractant. After the incubation at 37°C for 24
h (HuCCT-1) and 12 h (SSP-25), cells were fixed with 4% PFA at 20 min and stained with
hematoxylin and eosin. Cells that migrated through the pores to the lower surface of the filter were
15 counted under a microscope. A total of 3 random fields were counted in duplicate assays.
Chemosensitivity assay
NC and NRDC-KD ICC cells (HuCCT-1: 1.0×104 cells, SSP-25: 5.0×103 cells per well) were
20 seeded on 96-well plates in normal growth media. Twelve hours after seeding, gemcitabine was
added at the indicated concentrations. After a 72-h treatment, cell viability was examined using the
WST-8 assay. The cell viability ratio was defined as absorbance at 450 nm of the sample divided by
the absorbance of the control for each cell. All assays were performed in quadruplicate and repeated
at least three times.
25
Subcutaneous tumor xenograft
12
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Seven- to 9-week-old male nude mice were used as recipients for xenotransplantation. A total of
1.0×106 of HuCCT-1-NC, -KD1, or –KD2 cells were suspended in 100 μl phosphate-buffered saline
(PBS) and subcutaneously injected into the right (NC) and left (KD1 or KD2) flank of nude mice
5 (n=7, of each). Tumor sizes were measured every week after the inoculation. Tumor volumes were
calculated using the formula: length× (width) 2× 0.52. Animal experiments were performed in
accordance with the protocols approved by the Institutional Animal Care and Use Committee of
Kyoto University. Animal experiments were performed in accordance with the protocols approved
by the Institutional Animal Care and Use Committee of Kyoto University.
10
IHC
Four-micrometer-thick sections were incubated with an anti-human NRDC mouse monoclonal
antibody (#102, established in our laboratory) at 4 °C overnight. Envision polymer (DAKO), which
15 is a horseradish peroxidase-labeled polymer conjugated with an anti-mouse IgG antibody, was used
as a secondary antibody according to the manufacturer’s protocol. Color was developed with
diaminobenzidine solution (DAKO), followed by counterstaining with hematoxylin.
Quantitative real-time polymerase chain reaction (qRT- PCR)
20
Total RNA was isolated from HuCCT-1 and SSP-25 cells and 43 fresh frozen cancer tissues using
TRIzol reagent (Thermo Fisher, Scientific) and cleaned using the DNase set and RNeasy Mini Kit
(Qiagen, Hilden, Germany). cDNA generated by reverse transcription with the Omniscript RT Kit
(Qiagen) was subjected to a real-time polymerase chain reaction assay using the Step One Plus
25 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and Fast SYBR Green Master
Mix (Applied Biosystems) according to the manufacturer’s protocols. The average expression levels
13
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
of the target genes were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
using the 2−ΔΔCt method. The ICC cell line (SSP-25) was used as a reference sample (i.e.,
2−ΔΔCt value of SSP-25 cells=1) when analyzing human samples. The primers used in this
experiment are listed in Supplementary Table S1.
5
Western blotting
Twenty micrograms of cell lysates were electrophoresed on a 10% SDS-polyacrylamide gel (SDS
from Wako; acrylamide from Bio Rad, Hercules, CA, USA) and transferred to a nitrocellulose
10 membrane (GE Healthcare, Buckinghamshire, UK). The primary antibodies are listed
in Supplementary Table S2. The blot was observed with EZ-Capture II (ATTO, Tokyo, Japan)
visualized by ECL Prime (GE Healthcare). β-actin was used as the loading control. When analyzing
protein levels in CM, Ponceau 3R Stain Solution (Wako, Osaka, Japan) was used as the loading
control. In figures, representative images were selected from at least 3 independent experiments, in
15 which similar results were obtained.
Statistical analysis
Data from human clinical samples were expressed as median values (range). Regarding continuous
20 variables, data were expressed as a median (range), and compared using the Mann-Whitney U-
test. Categorical variables were expressed as a number [%] and compared using the χ2 test or
Fisher’s exact test where appropriate. A receiver operating characteristic (ROC) analysis was
performed to evaluate the discriminatory power of predictors. The area under the ROC curve
(AUC) was calculated. DeLong’s test was used to compare the AUC. The cut-off values, sensitivity,
25 and specificity of serum NRDC variables were assessed by the Youden index. Other cut-off values
were evaluated by clinically relevant values [5,6]. Relationships between continuous variables were
14
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
evaluated by Spearman’s correlation test (the value was expressed as ρ). To label the strength of the
relationship, for absolute values of ρ, 0-0.19 is regarded as very weak, 0.2-0.39 as weak, 0.40-0.59
as moderate, 0.6-0.79 as strong, and 0.8-1 as very strong [27]. OS was calculated from the day of
surgical resection to the date of death or end of the follow-up period, while disease-free survival
5 (DFS) was calculated using the date of death or recurrence as the time of the terminal event
according to the Kaplan-Meier method. Survival was compared using a generalized Wilcoxon test.
A multivariate analysis was performed by Cox’s regression (Step-wise backward model) for
variables identified as significant in the univariate analysis. When collinearity was encountered, a
choice was made based on the p value and clinical reasoning. All analyses were two-sided, and
10 differences were considered significant when p<0.05. Statistical analyses were performed using
JMP ver. 12.1 software (Cary, NC, USA).
Data from in vitro and in vivo experiments were analyzed using the Student’s t-test and expressed as
means ± standard deviation (SD). All statistical analyses were performed using JMP ver. 12.1
software (SAS Institute, Cary, NC, USA).
15
15
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Results
Prognostic impact of serum NRDC in ICC patients after surgical resection
5
In the primary cohort, serum NRDC levels were measured in 79 preoperative ICC patients who
consecutively underwent surgical resection at Kyoto University Hospital between 2006 and 2013.
In this study population, most patients had advanced stage disease (AJCC stage III/IV, n=52
[65.8%]) [24]. R0 resection was performed on 63 patients (79.7%) (Table S3). Serum NRDC levels
10 were significantly higher in ICC patients than in healthy controls (HC) (median; 1627.4 (range:
351.9-11318.7) pg/ml vs. 539.8 (range: 5.9-1184.2) pg/ml, p<0.001; Fig. 1A).
We then examined whether serum NRDC levels had prognostic value in ICC patients after
surgical resection. The median follow-up period was 41.6 months (range: 0.1-127.5 months). The
median OS time was 47.6 months, with 3- and 5-year OS rates of 57.0% and 42.3%, respectively.
15 The cut-off value for serum NRDC was selected as 1627.4 pg/ml based on the highest accuracy in
relation to an outcome (death) using an ROC analysis (AUC values of 0.688). Patients with ICC
were divided into two groups according to this cut-off value: high serum NRDC (n=40) and low
serum NRDC groups (n=39). High serum NRDC levels correlated with the presence of multiple
tumors (p=0.006) (Table 1). OS was significantly shorter in patients with high serum NRDC levels
20 than in those with low serum NRDC levels (p=0.002, Fig. 1B). The median OS and 3- and 5-year
survival rates of high and low serum NRDC groups were 31.0 versus 85.6 months, 57.0 versus
71.8%, and 22.3 versus 42.5%, respectively. Moreover, DFS was significantly shorter in patients
with high serum NRDC levels than in those with low serum NRDC levels (p=0.002, Fig. 1C). The
median DFS and 1- and 3-year DFS rates of the high and low serum NRDC groups were 9.4 versus
25 23.0 months, 42.5 versus 71.8%, and 15.0 versus 43.4%, respectively.
16
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
To confirm the prognostic relevance of serum NRDC as a biomarker, we performed
univariate and multivariate analyses by Cox’s hazard model using six potential confounders (Table
2). Among known prognostic factors [4-6], lymph node (LN) metastasis (p=0.001), vascular
invasion (p=0.033), and multiple tumors (p<0.001) were poor prognostic factors for OS. LN
5 metastasis (p=0.042), multiple tumors (p<0.001), and poor differentiation (p=0.026) were poor
prognostic factors for DFS. After the multivariate analysis, serum NRDC levels were maintained as
independent prognostic factors for OS (p=0.019) and DFS (p=0.009).
To validate the prognostic impact of NRDC in ICC patients, we analyzed serum NRDC
levels in an external independent cohort of 19 ICC patients who underwent surgical resection at
10 Hyogo College of Medicine between 2009 and 2015. (Table S4). The median follow-up period was
25.4 months (range: 3.8-70.6 months) and the median OS was 27.9 months, with 3- and 5-year OS
rates of 35.1 and 23.4%, respectively. Serum NRDC levels were significantly higher in the
validation cohort (median; 1330, range: 528-14597 pg/ml) than in HC, but were not significantly
different from those in the primary cohort (Fig. 1A). OS and DFS were significantly stratified
15 according to cut-off values (1295 pg/ml: AUC values of 0.729), which were selected independently
in the validation cohort by an ROC analysis. The clinical backgrounds of the high and low serum
NRDC groups and Kaplan-Meier curves for OS and DFS are shown in accordance with this
independent cut-off value (Table S5, Fig, 1D, E). These results reinforced the predictive value of
serum NRDC in postoperative ICC patients.
20
Comparison of serum NRDC levels with other tumor markers
Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are serum tumor
markers that are commonly measured in ICC patients [3, 5, 6]. A correlation was not observed
25 between serum NRDC and CEA or CA19-9 levels (Fig. S1). A Kaplan-Meier curve analysis
revealed that the elevated serum CEA (≥5 ng/mL) and CA19-9 (≥37 IU/ml) levels in ICC patients
17
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
correlated with a poor prognosis in the primary cohort (Fig. S2). An ROC analysis in relation to the
outcome (death) showed that the prognostic ability of preoperative serum NRDC levels (AUC:
0.689) was equivalent to that of serum CEA (0.569) and CA19-9 (0.671) levels (Fig. S3). We
additionally analyzed the prognostic value of the combination of 3 markers (Table S6) and found
5 that the combination of NRDC and CA19-9 provided the highest AUC value (0.756), which had a
significantly stronger prognostic value than CA19-9 alone (Fig. S4).
NRDC mRNA levels in resected cancerous tissue correlated with the prognosis of ICC patients
after surgical resection
10
The up-regulated expression of NRDC in cancer tissue has been reported to have a poor prognostic
impact in several cancer types [19, 22, 23]. In addition to serum NRDC levels, we examined NRDC
expression in surgical specimens resected from ICC patients. An IHC analysis showed the
membranous, cytosolic, and nuclear expression of NRDC in the cancer epithelium (Fig. 2A), which
15 was consistent with previous findings [12-20]. We quantified the mRNA expression levels of
NRDC in cancerous tissues from 43 ICC patients and analyzed the relationship with matched serum
NRDC levels. As expected, a correlation was observed between mRNA and serum NRDC levels
(ρ=0.413, p=0.006, Fig. 2B), suggesting that ICC tumors are a potential source of serum NRDC.
We also assessed the prognostic value of NRDC mRNA levels in tumors. The cut-off
20 values of mRNA levels were selected based on the highest accuracy in relation to the outcome of
death (cut-off 2-ΔΔCt value: 1.708, AUC value of 0.634) and were used to divide patients into two
groups: low NRDC mRNA (n=11) and high NRDC mRNA (n=32) groups. Using these cut-off
values (patient characteristics are shown in Table S7), OS and time to recurrence were significantly
shorter in patients with high NRDC mRNA levels than in those with low NRDC mRNA levels (Fig.
25 2C, D).
18
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Effects of the gene KD of NRDC on the proliferation, migration, and chemosensitivity of ICC
cells
We examined NRDC expression in 3 ICC cell lines and found that all cell lines strongly expressed
NRDC (Fig. S5). NRDC protein levels in ICC cells were similar to those in colon cancer HCT116
5 cells [28] and higher than those in 293T cells [13]. Therefore, to examine the pathophysiological
roles of NRDC in ICC cells, we performed gene KD experiments using 2 ICC cell lines with high
malignant potential: HuCCT-1 (obtained from metastatic ascites [29]) and SSP-25 (spindle cell-type
with mesenchymal features [30]). The sufficient silencing of NRDC expression in both cells was
confirmed by Western blotting and qRT-PCR analyses (Fig. 3A). Secreted NRDC in CM was also
10 clearly decreased by the gene KD (Fig. 3B). We initially evaluated cell proliferation using the
tetrazolium salt assay and found that the proliferation of HuCCT-1 and SSP-25 cells was
significantly decreased by the gene KD of NRDC (Fig. 3C). To further assess the impact of NRDC
on cell growth, control and NRDC-knocked down HuCCT-1 cells were used in tumor xenograft
experiments. Tumor growth after subcutaneous implantation was markedly less in cells with the
15 gene KD of NRDC than in control cells (Fig. 3D). Since we confirmed the similar effects of 2
different siRNAs on in vitro and in vivo cell proliferation, one (KD2) was selected for further
experiments. In two different assays (wound healing assay and chemotaxis assay), HuCCT-1 cells
in which NRDC was knocked down (NRDC-KD2) showed significantly less migratory potential
than control cells (NC) (Fig. 3E and 3F). The similar inhibitory effect of NRDC KD on cell
20 migration was also confirmed in SSP-25 cells (Fig. S6). Furthermore, the influence of NRDC levels
on the chemosensitivity of HuCCT-1 and SSP-25 cells to gemcitabine was investigated. In both cell
lines, NRDC-KD2 cells exhibited greater sensitivity to gemcitabine than NC cells (Fig. 3G and
Fig. S6).
25 Relationship between mRNA levels of NRDC and epithelial-mesenchymal transition (EMT)-
related genes in tumor tissues from ICC patients
19
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
To gain mechanical insights into the tumor-promoting and chemoresistant potential of NRDC in
ICC, we investigated gene profiles in ICC cell lines. An analysis by qRT-PCR revealed that several
EMT- and cancer stem cell (CSC)-related genes were down-regulated by the gene KD of NRDC in
5 HuCCT-1 (Fig. 4A) and SSP-25 cells (Fig. 4B). For example, the mRNA levels of vimentin, a
marker of mesenchymal cells, zinc finger E-box-binding homeobox 1 (ZEB1), an EMT-inducing
transcription factor (EMT-TF), sex-determining region Y-box 2 (SOX2), a marker of CSC, and
hypoxia-inducible factor-1α (HIF-1), a trigger of the EMT pathway, were down-regulated by the
gene KD of NRDC. Other EMT-TF, SNAI1 and TWIST1, were also significantly decreased by
10 NRDC KD in SSP-25 cells (Fig. 4B). The Western blot analysis revealed that the protein expression
levels of these genes were markedly reduced (Fig. 4A, B), while E-cadherin, a marker of epithelial
cells, was increased by NRDC KD in HuCCT-1 cells (Fig. 4A).
We then investigated whether relationships existed between the mRNA levels of NRDC
and EMT-related genes in tumor tissues from ICC patients. Notably, the expression levels of NRDC
15 positively and strongly correlated with two EMT-TFs, ZEB1 (ρ=0.679, p<0.001) and SNAI1
(ρ=0.647, p<0.001), and HIF-1α expression (ρ=0.721, p<0.001) (Fig. 4C). NRDC mRNA levels
correlated with SOX2 expression, but not with TWIST1 expression or the Vimentin/E-cadherin
ratio (Fig. S7). We then examined the relationship between serum NRDC and mRNA levels of
EMT-related genes in tumor tissues. Serum NRDC positively correlated with SNAI1
20 (ρ=0.327, p=0.032) and HIF-1α (ρ=0.301, p=0.050) mRNA levels in surgical specimens. ZEB1
mRNA levels were also positively associated with serum NRDC levels (ρ=0.287, p=0.062) (Fig.
4D). Therefore, serum NRDC has potential as a surrogate marker for EMT in the tumors of ICC
patients.
20
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Discussion
The present study highlights the clinical implications of preoperative serum NRDC measurements
in ICC patients, which may contribute to the identification of patients with a poor prognosis. OS
and DFS were significantly stratified by serum NRDC levels in the primary (development) and
5 validation cohorts. The expression levels of NRDC in sera and cancerous tissues were significantly
linked; therefore, an evaluation of pathophysiological features in resected tissues provided an
insight into the clinical significance of serum NRDC. NRDC mRNA levels correlated with EMT-
related genes in primary tumors. Moreover, direct correlations were observed between serum
NRDC and mRNA levels of major EMT-TF, suggesting that serum NRDC has potential as a
10 surrogate marker for EMT features in primary tumors. This hypothesis was supported by a cell
analysis because the gene silencing of NRDC in ICC cell lines reduced EMT-related gene
expression. Functionally, the gene KD of NRDC was accompanied by attenuated
proliferation/migration and increased chemosensitivity to gemcitabine. Importantly, a correlation
was not noted between serum NRDC and CA19-9 or CEA, currently available prognostic markers
15 for ICC. Furthermore, the combination of NRDC and CA19-9 had stronger prognostic value than
either marker analyzed individually, suggesting that serum NRDC is a unique prognostic marker for
ICC patients after surgical resection.
Based on the prognostic impact of serum NRDC levels in ICC patients after surgical
resection, the source of NRDC in serum needs to be identified. According to the following findings
20 of clinical studies: 1) serum NRDC levels were significantly higher in ICC patients than in HC, 2) a
correlation between serum NRDC and NRDC expression levels in resected cancer tissue, we
speculate that a potential source of serum NRDC may be the ICC tumor itself. Experiments using
ICC cell lines also revealed that NRDC is secreted into CM, the amount of which correlated with
the intracellular expression level of NRDC. Our previous analysis of patients with HCC also
25 suggested that serum NRDC reflected the amount of NRDC in cancer tissues [23]. Another possible
source of serum NRDC is inflammatory cells adjacent to tumors. We recently reported that NRDC
21
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
levels were increased in the synovial fluid of patients with rheumatoid arthritis [31]. NRDC in
macrophages regulates arthritis via the control of TNF-α secretion because the macrophage-specific
deletion of NRDC markedly ameliorated arthritis [30]. We also demonstrated that inflammatory
cells infiltrating the infarcted myocardium strongly express NRDC [25]. However, clinical data
5 from this study do not strongly support this hypothesis because pre-operative C-reactive protein
levels in ICC patients did not correlate with serum NRDC levels (data not shown). In any case,
serial measurements of serum NRDC levels after surgical resection are needed to identify the real
source, which will also further clarify the relationship between serum NRDC levels and tumor
recurrence.
10 The significant link between patient prognosis and NRDC mRNA expression levels in
cancerous tissues prompted us to examine the pathophysiological functions of NRDC in ICC cells.
The gene KD of NRDC in two different ICC cell lines attenuated cell proliferation and migration,
indicating important roles for NRDC in ICC progression. Moreover, the gene KD of NRDC in
HuCCT-1 cells resulted in increased sensitivity to gemcitabine. Since the poor prognosis of ICC
15 patients is mainly attributed to its highly metastatic characteristics, EMT in the pathogenesis of ICC
has been attracting increasing attention from researchers [32]. Accumulated evidence also suggests
a relationship between chemoresistance and the acquisition of the EMT phenotype and/or existence
of CSC within the tumor [33]. Among EMT-related genes, the significance of EMT-TF, such as
ZEB1, SNAI1, and TWIST1, has been emphasized [32-36]. An analysis of surgical specimens also
20 demonstrated that the strong expression of EMT-TF in resected tissue is associated with the poor
prognosis of ICC patients after surgical resection [32]. We herein showed that the gene KD of
NRDC was accompanied by marked reductions in several EMT-related genes. Moreover, strong
correlations between NRDC and EMT-related genes (ZEB1, SNAI1, and HIF-1α) were
recapitulated in resected cancerous tissue from ICC patients. Park et al. very recently demonstrated
25 that NRDC regulated EMT-related genes, including SNAI1, in colon cancer cells [37]; NRDC was
responsible for the insulin-like growth factor-1 (IGF-1)-induced regulation of EMT-related genes.
22
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Together with our in vitro and in vivo data from ICC cells, NRDC appears to play important and
general roles in the regulation of EMT.
Several signaling pathways triggered, for example, by transforming growth factor-β (TGF-
β) and epidermal growth factor (EGF) as well as hypoxia may induce EMT [35,36]. These signals
5 lead to the activation of EMT-TF, such as ZEB1, SNAI1, and TWIST1, which directly or indirectly
control key EMT-related genes. Due to the multiple functions of NRDC, there are several
possibilities by which NRDC is involved in EMT. Extracellular NRDC may activate EGF or TNF
receptor signaling by enhancing the ectodomain shedding of EGF receptor ligands or TNF-α,
respectively [12,13,18]. Furthermore, nuclear NRDC may regulate the transcription of EMT-related
10 genes, including EMT-TF [38, 39]. While the underlying mechanisms have not yet been elucidated
in detail, the present results suggest that elevated NRDC levels in cancer tissue are associated with
EMT programs. Based on the positive correlation between serum and tumor NRDC levels, it may
be possible to assess the level of EMT features in primary tumors by measuring serum NRDCs.
In conclusion, this is the first study to demonstrate that serum NRDC has potential as a
15 novel prognostic biomarker for ICC, which may reflect EMT features in primary tumor regions. We
propose that the preoperative evaluation of serum NRDC is a potential clinical tool for predicting
tumor recurrence in and the overall prognosis of patients after curative-intent surgery.
23
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Acknowledgments
We gratefully acknowledge the patients who consented to blood collection for this study. The
detection of serum NRDC was supported by Yoshiyuki Amano (Sanyo Chemical Industries). We
thank Takayuki Kawai, Takahiro Nishio, Masayuki Okuno, Seidai Wada, Asahi Sato, Yoshinobu
5 Ikeno, Yusuke Morita, Shintaro Matsuda, and Hiromi Iwai (Kyoto University) for their excellent
help. This study was financially supported by Grants-in-Aid KAKENHI (17H04048, 17K09575,
17K16147, and 18H04694) and AMED (JP17cm0106608). It was also supported by the Takeda
Science Foundation, SENSHIN Medical Research Foundation, and Suzuken Memorial Foundation.
10
24
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
References
1. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach
to cholangiocarcinoma: A systematic review of the current literature. J Am Coll Surg 2009; 208:
134-147.
5 2. Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, et al. Report of the 19th follow-up
survey of primary liver cancer in Japan. Hepatol Res. 2016; 46: 372-90.
3. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the
diagnosis and management of intrahepatic cholangiocarcinoma. J.Hepatology 2014; 60: 1268–1289.
4. Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM.
10 Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. 2013; 119: 3929-3942.
5. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for Patients
with Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg 2014;
149: 565–574.
6. Yoh T, Hatano E, Yamanaka K, Nishio T, Seo S, Taura K, et al. Is Surgical Resection Justified for
15 Advanced Intrahepatic Cholangiocarcinoma? Liver Cancer 2016; 5: 280–289.
7. Yoh T, Hatano E, Nishio T, Seo S, Taura K, Yasuchika K, et al. Significant Improvement in
Outcomes of Patients with Intrahepatic Cholangiocarcinoma after Surgery. World J Surg. 2016; 9:
2229-2236.
8. Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, et al. Chemotherapy for
20 surgically resected intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2015; 22:3716–3723
9. Yoh T, Seo S, Hatano E, Taura K, Fuji H, Ikeno Y, et al. A Novel Biomarker-Based Preoperative
Prognostic Grading System for Predicting Survival After Surgery for Intrahepatic
Cholangiocarcinoma. Ann Surg Oncol. 2017; 24: 1351-1357.
10. Yamashita S, Passot G, Aloia TA, Chun YS, Javle M, Lee JE, et al. Prognostic value of
25 carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg. 2017;
104: 267-277.
25
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
11. Bergquist JR, Ivanics T, Storlie CB, Groeschl RT, Tee MC, Habermann EB, et al. Implications
of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic
cholangiocarcinoma: A national cohort analysis. J Surg Oncol. 2016; 114: 475-82.
12. Nishi E, Prat A, Hospital V, Elenius K, Klagsbrun M. N-arginine dibasic convertase is a specific
5 receptor for heparin-binding EGF-like growth factor that mediates cell migration. EMBO J. 2001;
20: 3342-50.
13. Nishi E, Hiraoka Y, Yoshida K, Okawa K, Kita T. Nardilysin enhances ectodomain shedding of
heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis
factor-alpha-converting enzyme. J Biol Chem. 2006; 281: 31164-72.
10 14. Ohno M, Hiraoka Y, Lichtenthaler SF, Nishi K, Saijo S, Matsuoka T, et al. Nardilysin prevents
amyloid plaque formation by enhancing α-secretase activity in an Alzheimer's disease mouse
model. Neurobiol Aging. 2014; 35: 213-22.
15. Hiraoka Y, Matsuoka T, Ohno M, Nakamura K, Saijo S, Matsumura S, et al. Critical roles of
nardilysin in the maintenance of body temperature homoeostasis. Nat Commun. 2014; 5: 3224. doi:
15 10.1038/ncomms4224.
16. Nishi K, Sato Y, Ohno M, Hiraoka Y, Saijo S, Sakamoto J, et al. Nardilysin Is Required for
Maintaining Pancreatic β-Cell Function. Diabetes. 2016; 65: 3015-27.
17. Ma Z, Chow KM, Yao J, Hersh LB. Nuclear shuttling of the peptidase nardilysin. Arch Biochem
Biophys 2004; 422: 153–16012.
20 18. Hiraoka Y, Yoshida K, Ohno M, Matsuoka T, Kita T, Nishi E. Ectodomain shedding of TNF-
alpha is enhanced by nardilysin via activation of ADAM proteases. Biochem Biophys Res
Common. 2008; 370: 154-8.
19. Kanda K, Komekado H, Sawabu T, Ishizu S, Nakanishi Y, Nakatsuji M, et al. Nardilysin and
ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via
25 enhanced ectodomain shedding of TNF-α. EMBO Mol Med. 2012; 4: 396-411.
26
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
20. Li J, Chu M, Wang S, Chan D, Qi S, Wu M, et al. Identification and characterization of
nardilysin as a novel di-methyl H3K4-binding protein involved in transcriptional regulation. J Biol
Chem. 2012; 287: 10089-98.
21. Choong LY, Lim SK, Chen Y, Loh MC, Toy W, Wong CY, et al. Elevated NRD1
5 metalloprotease expression plays a role in breast cancer growth and proliferation. Genes
Chromosomes Cancer. 2011; 50: 837-47.
22. Uraoka N, Oue N, Sakamoto N, Sentani K, Oo HZ, Naito Y, et al. NRD1, which encodes
nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and
MMP3 expression. Cancer Sci. 2014; 105: 134-40.
10 23. Kasai Y, Toriguchi K, Hatano E, Nishi K, Ohno M, Yoh T, et al. Nardilysin promotes
hepatocellular carcinoma through activation of signal transducer and activator of transcription 3.
Cancer Sci. 2017; 108: 910-917.
24. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th Edition of the
AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol 2010; 17: 1471–1714.
15 25. Chen PM, Ohno M, Hiwasa T, Nishi K, Saijo S, Sakamoto J, et al. Nardilysin is a promising
biomarker for the early diagnosis of acute coronary syndrome. Int J Cardiol. 2017; 243: 1-8.
26. Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, Ogiso S, et al. Keratin 19, a Cancer
Stem Cell Marker in Human Hepatocellular Carcinoma. Clin Cancer Res. 2015; 21: 3081-91.
27. Evans JD. Straightforward statistics for the behavioral sciences. 1996. Brooks/Cole, Pacific
20 Grove.
28. Kanda K, Sakamoto J, Matsumoto Y, Ikuta K, Goto N, Morita Y, et al. Nardilysin controls
intestinal tumorigenesis through HDAC1/p53-dependent transcriptional regulation. JCI Insight.
2018; 3 (8): e91316.
29. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma
25 cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev
Biol. 1989; 25: 503-10
27
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
30. Fukutomi M, Enjoji M, Iguchi H, Yokota M, Iwamoto H, Nakamuta M, et al. Telomerase
activity is repressed during differentiation along the hepatocytic and biliary epithelial lineages:
verification on immortal cell lines from the same origin. Cell Biochem Funct. 2001; 19: 65-8.
31. Fujii T, Nishi E, Ito H, Yoshitomi H, Furu M, Okabe N, et al. Nardilysin is involved in
5 autoimmune arthritis via the regulation of tumour necrosis factor alpha secretion. RMD Open.
2017; 3: e000436.
32. Vaquero J, Guedj N, Clapéron A, Nguyen Ho-Bouldoires TH, Paradis V, Fouassier L. Epithelial-
mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. J
Hepatol. 2017; 66: 424-441.
10 33. Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, et al. The
EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreaticcancer.
Nat Cell Biol. 2017; 19: 518-529.
34. Liu Y, Lu X, Huang L, Wang W, Jiang G, Dean KC, et al. Different thresholds of ZEB1 are
required for Ras-mediated tumour initiation and metastasis. Nat. Commun. 2014; 5: 5660.
15 35. Polyak K, Weinberg RA. Epithelial- Transitions between epithelial and mesenchymal states:
acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265–273.
36. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in
development and disease. Cell 2009; 139: 871–890.
37. Park GB, Kim D. Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K
20 in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition
through the regulation of ADAM10 and ADAM17. Mol Cell Biochem. 2018 ;439:199-211.
38. Eom S, Kim Y, Park D, Lee H, Lee YS, Choe J, et al. Histone Deacetylase-3 Mediates Positive
Feedback Relationship between Anaphylaxis and Tumor Metastasis J Biol Chem. 2014; 289:
12126–12144.
28
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
39. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-
1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014; 10: 992-1003.
29
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Table 1
Clinicopathological characteristics and surgical outcomes according to serum NRDC levels
NRDC low NRDC high Variables p value n = 39 n = 40
Clinical factors
Age (years) 69 (32-84) 67.5 (37-83) 0.677
Gender (Male) 23 (58.9%) 26 (65.0%) 0.581
Hepatitis B † 3 (7.7%) 1 (2.5%) 0.356
Hepatitis C † 7 (17.9%) 3 (7.5%) 0.193
CA19-9 (IU/ml) 35.2 (0-5461.1) 75.4 (0-1788.0) 0.111
CEA (ng/ml) 2.1 (0.4-23.7) 2.95 (0-116.6) 0.310
Histological factors
Tumor diameter (cm) 4.1 (1.0-9.0) 4.6 (1.0-14.0) 0.157
Multiple tumors 3 (7.7%) 13 (32.5%) 0.006*
LN metastasis 9 (23.1%) 12 (30.0%) 0.486
Poor differentiation† 2 (5.1%) 7 (17.5%) 0.154
Vascular invasion 20 (51.3%) 24 (60.0%) 0.314
Biliary invasion 18 (46.2%) 17 (42.5%) 0.744
AJCC T3/T4 22 (56.4%) 21 (52.5%) 0.727
AJCC stage III/IV 25 (64.1%) 27 (67.5%) 0.750
Surgical outcomes
R0 resection 32 (82.1%) 31 (77.5%) 0.615
Major hepatectomy (≥3 segments) 34 (87.2%) 35 (87.5%) 1.000
Adjuvant chemotherapy 16 (41.0%) 23 (59.0%) 0.143
Morbidity 17 (43.6%) 18 (45.0%) 0.900
Mortality (<30 days) † 0 (0%) 1 (2.5%) 1.000
* Significant difference p<0.05 † Fisher’s exact test and the χ2 test were used for all other categorical variables. Abbreviations: NRDC, nardilysin; CA19-9, carbohydrate antigen 19-9; CEA, Carcinoembryonic antigen; LN, lymph node; AJCC, American Joint Committee on Cancer; R0, no residual tumor
30
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Table 2
Univariate and multivariate analyses of factors predicting postoperative prognosis
Univariate analysis Multivariate analysis Variables Hazard ratio p value p value (95% Confidence Interval)
Survival
High serum NRDC (versus low) 0.002* 2.047 (1.126-3.821) 0.019* LN metastasis (versus N0/Nx) 0.001* 1.942 (1.032-3.584) 0.040* Vascular invasion (versus negative) 0.033* - - Multiple tumors (versus solitary) <0.001* 2.548 (1.066-4.226) 0.033*
Poor differentiation (versus well/moderate) 0.176 - -
Tumor size ≥5 cm (versus <5 cm) 0.873 - -
Recurrence
High serum NRDC (versus low) <0.001* 2.017 (1.189-3.470) 0.009*
LN metastasis (versus N0/Nx) 0.042* - -
Vascular invasion (versus negative) 0.619 - -
Multiple tumors (versus solitary) <0.001* 2.397 (1.279-4.289) 0.008*
Poor differentiation (versus well/moderate) 0.026* - -
Tumor size ≥5 cm (versus <5 cm) 0.617 - -
* Significant difference p<0.05 Abbreviations: NRDC, nardilysin; LN, lymph node; N0, negative for nodal metastasis; Nx, nodal metastasis status undetermined
31
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Figure Legends
Figure 1
5 Prognostic impact of serum NRDC levels in ICC patients after surgical resection
A. Comparison of serum NRDC levels in HC (n=112) and ICC patients in the primary (n=79) and
validation (n=19) cohorts.
B, C. Kaplan-Meier analyses for OS (B) and DFS (C) in 79 ICC patients in the primary cohort
10 according to serum NRDC levels.
D, E. Kaplan-Meier analyses for OS (B) and DFS (C) in 19 ICC patients in the external validation
cohort according to serum NRDC levels.
NRDC, nardilysin; ICC, intrahepatic cholangiocarcinoma; HC, healthy controls; OS, overall
15 survival; DFS, disease-free survival.
32
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Figure 2
NRDC mRNA levels in resected cancerous tissue correlate with the prognosis of ICC patients
after surgical resection
5
A. Immunohistochemical staining of NRDC in surgical specimens of ICC. The scale bar represents
100 µm.
B. Relationship between serum NRDC and NRDC mRNA expression in cancer tissue.
C, D. Kaplan-Meier analyses for OS (C) and DFS (D) in 43 ICC patients according to NRDC
10 mRNA levels in resected cancerous tissue.
NRDC, nardilysin; ICC, intrahepatic cholangiocarcinoma; OS, overall survival, DFS, disease-free
survival
15
33
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Figure 3
Effects of the gene knockdown of NRDC on the proliferation, migration, and chemosensitivity of
ICC cells
5
A. Stable NRDC-KD ICC cells were established. qRT-PCR and Western blotting were then
performed to confirm the expression of NRDC.
B. NRDC secreted in CM was decreased by the gene KD of NRDC in HuCCT-1 and SSP-25 cells.
C, D. Silencing NRDC attenuated cell proliferation in vitro and tumor growth in vivo (D).
10 E, F. Wound healing assays (E) and chemotaxis assays (F) demonstrated that the migratory ability
of HuCCT-1 cells was decreased by the gene KD of NRDC.
G. Effects of gemcitabine concentrations on the viability of HuCCT-1 cells. Silencing NRDC
increased chemosensitivity.
Data represent the mean ± SD of at least three independent experiments; *p<0.05. **p<0.01.
15
NRDC, nardilysin; ICC, intrahepatic cholangiocarcinoma; KD, knockdown; CM, condition medium
34
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Figure 4
Relationship between NRDC and epithelial-mesenchymal transition (EMT)-related genes in ICC
5
A, B. qRT-PCR and Western blot analyses were performed to assess the mRNA and protein levels
of EMT-related genes in NC versus NRDC KD2 in HuCCT-1 cells (A) and SSP-25 cells (B). Data
represent the mean ± SD of at least three independent experiments; *p<0.05. **p<0.01. In Western
blotting, representative images are selected from 3 independent experiments, in which similar
10 results were obtained.
C. Correlation analysis between the mRNA levels of NRDC and EMT-related genes (ZEB1,
SNAI1, and HIF-1α) in surgical specimens from ICC patients.
D. Correlation analysis between the serum NRDC and mRNA levels of EMT-related genes (ZEB1,
SNAI1, and HIF-1α) in surgical specimens from ICC patients.
15
NRDC, nardilysin; EMT, epithelial-mesenchymal transition; ICC, intrahepatic cholangiocarcinoma;
NC, negative control; KD, knockdown; SD, standard deviation
35
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1078-0432.CCR-18-0124 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Serum nardilysin, a surrogate marker for epithelial-mesenchymal transition, predicts prognosis of intrahepatic cholangiocarcinoma after surgical resection
Tomoaki Yoh, Etsuro Hatano, Yosuke Kasai, et al.
Clin Cancer Res Published OnlineFirst October 23, 2018.
Updated version Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-18-0124
Supplementary Access the most recent supplemental material at: Material http://clincancerres.aacrjournals.org/content/suppl/2018/10/23/1078-0432.CCR-18-0124.DC1
Author Author manuscripts have been peer reviewed and accepted for publication but have not yet Manuscript been edited.
E-mail alerts Sign up to receive free email-alerts related to this article or journal.
Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications Subscriptions Department at [email protected].
Permissions To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2018/10/23/1078-0432.CCR-18-0124. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.
Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research.